Patents by Inventor Novartis AG

Novartis AG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140363506
    Abstract: Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.
    Type: Application
    Filed: November 26, 2012
    Publication date: December 11, 2014
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130345180
    Abstract: There are provided compounds of formula I wherein X, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as indicated in claim 1, useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 26, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130224309
    Abstract: The present invention provides methods for making an antimicrobial medical device, preferably an antimicrobial ophthalmic device, more preferably an antimicrobial extended-wear contact lens, which contains silver nano-particles distributed uniformly therein. The antimicrobial medical device can exhibit antimicrobial activity over an extended period of time.
    Type: Application
    Filed: March 19, 2013
    Publication date: August 29, 2013
    Inventor: NOVARTIS AG
  • Publication number: 20130226293
    Abstract: In one aspect, an accommodative intraocular lens (IOL) is disclosed that includes an optic having at least a portion formed of a polarizable and/or and electro-active material. Once implanted in a subject's eye, a change in the index of refraction of the polarizable and/or electro-active portion in response to forces applied to the optic via the eye's ciliary muscle can cause a change in the optical power of the optic, thereby allowing accommodation.
    Type: Application
    Filed: February 25, 2013
    Publication date: August 29, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG
  • Publication number: 20130225574
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: February 22, 2013
    Publication date: August 29, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130217719
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: February 7, 2013
    Publication date: August 22, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG
  • Publication number: 20130217859
    Abstract: NMB 1870 is a protein in Neisseria meningitidis. Three families of NMB 1870 are known. To increase the ability of a NMB1870 protein to elicit antibodies that are cross-reactive between the families, NMB1870 is engineered. Sequences can be substituted from one NMB1870 family into the corresponding position in another family. Proteins of NMB1870 sequences from different families can be joined to each other.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 22, 2013
    Applicant: NOVARTIS AG
    Inventor: NOVARTIS AG
  • Publication number: 20130210771
    Abstract: This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit.
    Type: Application
    Filed: February 13, 2013
    Publication date: August 15, 2013
    Applicant: IRM LLC
    Inventor: Novartis AG
  • Publication number: 20130211435
    Abstract: A surgical system that is able to sense the onset of an occlusion or other surgical event as well as the instant an occlusion breaks. To help avoid overheating of the tip, the system determines an approximate temperature of the eye using an irrigation flow rate and reduces the power to the handpiece automatically if an overheating situation is predicted. Alternatively or in addition, the system monitors the power drawn by the handpiece, which is indicative of the cutting load on the tip, and automatically adjusts the power to the tip to compensate for increased loads on the tip.
    Type: Application
    Filed: October 31, 2012
    Publication date: August 15, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG
  • Publication number: 20130189300
    Abstract: The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a spr0096 antigen and a spr2021 antigen. spr0096 and spr2021 are Streptococcus pneumoniae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.
    Type: Application
    Filed: November 7, 2012
    Publication date: July 25, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130184282
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: July 18, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130182038
    Abstract: The present invention generally relates to a printing apparatus including one or more print heads for depositing printing fluid onto a substrate, wherein the apparatus comprises a maintenance unit for the one or more print heads. The present invention further relates to a method for cleaning one or more print heads from adhering printing fluid. The present invention also relates to the use of said apparatus in the automated manufacture of a contact lens, in particular a silicone hydrogel contact lens.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 18, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG
  • Publication number: 20130184285
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: March 6, 2013
    Publication date: July 18, 2013
    Applicants: ASTEX THERAPEUTICS, NOVARTIS AG
    Inventors: NOVARTIS AG, ASTEX THERAPEUTICS
  • Publication number: 20130178789
    Abstract: A method and apparatus to operate a surgical instrument in response to a thermal condition being detected that warrants curtailment of further operation. When the thermal condition is reached, command signals are generated that cause a needle of the surgical instrument to either have its vibrational speed slowed, have its vibrational movement stopped, or have it withdrawn from its relative position. The detection is of infrared radiation wavelengths and is carried out with either a thermal imaging device or a thermal recognition device. A corresponding temperature of the detected infrared radiation wavelengths is compared to a critical temperature to determine whether the thermal condition has been reached.
    Type: Application
    Filed: February 12, 2013
    Publication date: July 11, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130175721
    Abstract: The present invention generally relates to a method for making colored contact lenses, in particular to colored silicone hydrogel contact lenses. The present invention is also related to a method of a first high intensity UV curing the colored print on the mold and a second high intensity UV treating mold for making colored silicone hydrogel contact lenses. The present invention illustrates the right combination of the first high intensity UV exposure and the second high intensity UV exposure allows a lens that maintains good ion permeability (IP) value and a good print quality.
    Type: Application
    Filed: December 13, 2012
    Publication date: July 11, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130178518
    Abstract: The instant invention pertains to a method for producing contact lenses with improved oxidative stability of Carotenoids in the contact lens. The method of the invention involves adding a vitamine E material into a contact lens in an amount sufficient to reduce oxidative degradation of Carotenoids in the lens by at least about 30% in comparison with an identical contact lens without the vitamin E material.
    Type: Application
    Filed: December 17, 2012
    Publication date: July 11, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130171238
    Abstract: The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for eliciting a Chlamydia trachomatis specific TH2 immune response. The invention further relates to an immunogenic composition comprising a Chlamydia trachomatis Type III secretion system (TTSS) regulatory protein and a Chlamydia trachomatis Type III secretion system (TTSS) secreted protein or a fragment thereof. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif.
    Type: Application
    Filed: January 4, 2013
    Publication date: July 4, 2013
    Applicant: NOVARTIS AG
    Inventor: NOVARTIS AG
  • Publication number: 20130171167
    Abstract: This invention relates to methods employing IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 4, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG
  • Publication number: 20130172504
    Abstract: The invention provide a new class of silicone-containing prepolymers containing ethylenically unsaturated groups and latent UV-activated free radical generating moieties. This class of silicone-containing prepolymer is capable of being actinically crosslinked in the presence of one or more hydrophilic vinylic monomers to form a silicone hydrogel material with a hydrophilic surface without post curing surface treatment. The present invention is also related to silicone hydrogel contact lenses made from this class of silicone-containing prepolymers and a vinylic monomer having a latent UV-activated free radical generating moiety.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 4, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG
  • Publication number: 20130172349
    Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: February 22, 2013
    Publication date: July 4, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG